NeurogesX Inc. (NGSX) Q1 2010 Earnings Call Transcript May 11, 2010 4:30 pm ET Executives Carol Ruth – IR, The Ruth Group Tony DiTonno – President & CEO Stephen Ghiglieri – EVP, COO & CFO Analysts Andrew Vaino – ROTH Capital Michael Higgins – Rodman & Renshaw PresentationOperator
Greetings and welcome to the NeurogesX Inc. first quarter 2010 earnings conference call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator instructions) as a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Carol Ruth of the Ruth Group. Thank you. You may begin. Carol Ruth Thank you, operator. Joining us on the call today are Tony DiTonno, Chief Executive Officer, and Stephen Ghiglieri, Executive Vice president, Chief Operating Officer and Chief Financial Officer. Statements in this conference call regarding NeurogesX’s business, which are not historical facts, may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 or the act. NeurogesX disclaims any intent or obligation to update these forward-looking statements and claims protection of the Safe Harbor for forward-looking statements contained in the act. Forward-looking statements may include, but are not limited to, statements regarding plan; commercialization and sales strategies; as well as the expected benefits of success strategy and the effects of strategies may have on sales and revenue expectations; expectations regarding reimbursement for Qutenza, including the receipt and timing of any product-specific; reimbursement code; the estimated usage profile of patients, that may use Qutenza and physicians that may prescribe Qutenza; sales and marketing expenses for 2010 and into 2011, including the rate of increase in the such expenses over 2010 and into 2011; the timing and scope of commercial launch of Qutenza in the United States and European Union; the roles and activities of Astellas in commercialization of Qutenza in the European Union; the timing of reentry of NGX-1998 into clinical development; the sufficiency of cash resources to fund the Company’s operations into 2011 and expected source of capital.